Incidence and Risk Factors for Eosinophilia and Lung Disease in Biologic‐Exposed Children With Systemic Juvenile Idiopathic Arthritis

Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction

(2022) Marco Giuseppe Del Buono et al.   Scientific Reports

2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis

(2022) Karen B. Onel et al.   ARTHRITIS CARE & RESEARCH

The Conundrum of Lung Disease and Drug Hypersensitivity‐like Reactions in Systemic Juvenile Idiopathic Arthritis

(2022) Bryce A. Binstadt et al.   Arthritis & Rheumatology

IFN-γ is essential for alveolar macrophage–driven pulmonary inflammation in macrophage activation syndrome

(2021) Denny K. Gao et al.   JCI Insight

Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles

(2021) Vivian E Saper et al.   ANNALS OF THE RHEUMATIC DISEASES

Treat-to-target using first-line recombinant interleukin-1 receptor antagonist monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five year follow-up study

(2019) Nienke M. ter Haar et al.   Arthritis & Rheumatology

The REDCap consortium: Building an international community of software platform partners

(2019) Paul A. Harris et al.   JOURNAL OF BIOMEDICAL INFORMATICS

IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome

(2019) Shima Yasin et al.   RHEUMATOLOGY

Emergent high fatality lung disease in systemic juvenile arthritis

(2019) Vivian E Saper et al.   ANNALS OF THE RHEUMATIC DISEASES

Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease: Characterization and Risk Factors

(2019) Grant S. Schulert et al.   Arthritis & Rheumatology

Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications

(2016) Michael J Ombrello et al.   ANNALS OF THE RHEUMATIC DISEASES

2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborat

(2016) Angelo Ravelli et al.   Arthritis & Rheumatology

Drug-induced hypereosinophilia related to tocilizumab therapy for rheumatoid arthritis: Fig. 1

(2015) Kathleen Morrisroe et al.   RHEUMATOLOGY

Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients

(2014) Francesca Minoia et al.   Arthritis & Rheumatology

Review: Is There a Window of Opportunity for Treatment of Systemic Juvenile Idiopathic Arthritis?

(2014) Peter A. Nigrovic   Arthritis & Rheumatology

Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis

(2012) Esi Morgan DeWitt et al.   ARTHRITIS CARE & RESEARCH

Pulmonary Hypertension and Other Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis

(2012) Yukiko Kimura et al.   ARTHRITIS CARE & RESEARCH

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series

(2010) Peter A. Nigrovic et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

(2008) Shumpei Yokota et al.   LANCET